If he will list those illnesses and conditions for which the Prodigy prescribing pilot system is able to print information leaflets; and if he will list the patient groups which have been consulted while developing the patient information provided under the Prodigy prescribing pilot system.

If he will list those illnesses and conditions for which the Prodigy prescribing pilot system is able to print information leaflets; and if he will list the patient groups which have been consulted while developing the patient information provided under the Prodigy prescribing pilot system.

What assessment he has made of the impact of the extension of the Prodigy pilot study on (a) inward investment by non-United Kingdom-owned pharmaceutical companies, (b) research and development expenditure by the United Kingdom pharmaceutical industry, (c) export performance by the United Kingdom pharmaceutical industry and (d) the introduction in...

What assessment he has made of the impact of the extension of the Prodigy pilot study on (a) inward investment by non-United Kingdom-owned pharmaceutical companies, (b) research and development expenditure by the United Kingdom pharmaceutical industry, (c) export performance by the United Kingdom pharmaceutical industry and (d) the introduction in...

If he will list how the money allocated by his Department to the Prodigy project is being spent; and what sums are being contributed by the participating IT software companies.

If he will list how the money allocated by his Department to the Prodigy project is being spent; and what sums are being contributed by the participating IT software companies.

If he will list (a) the numbers and types of general practices participating in the Prodigy project, (b) their locations by region or district and (c) their fundholding status; and if he will comment on how the practices were chosen.

If he will list (a) the numbers and types of general practices participating in the Prodigy project, (b) their locations by region or district and (c) their fundholding status; and if he will comment on how the practices were chosen.

If he will list the IT software companies participating in the Prodigy project.

If he will list the IT software companies participating in the Prodigy project.

What is his policy on the establishment of a national formulary for prescribing, and if he intends the Prodigy project to be a pilot for a formulary.

What is his policy on the establishment of a national formulary for prescribing, and if he intends the Prodigy project to be a pilot for a formulary.

What is the aim of the Prodigy project.

What is the aim of the Prodigy project.

What representations, and from whom, he has so far received on the Prodigy project.

What representations, and from whom, he has so far received on the Prodigy project.

How many of the medicines listed in the Prodigy project are (a) generic and (b) brand named; and how this balance was reached.

How many of the medicines listed in the Prodigy project are (a) generic and (b) brand named; and how this balance was reached.